Compounds > indazoles
Page last updated: 2024-08-21

indazoles and azd 6244

indazoles has been researched along with azd 6244 in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (90.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Beale, GS; Haagensen, EJ; Kyle, S; Maxwell, RJ; Newell, DR1
Bentires-Alj, M; Brachmann, SM; Elain, G; Hofmann, F; Hofmann, I; Lai, A; Maira, SM; Roberts, TM; Romanet, V; Schmelzle, T; Schwaederle, M; Sellers, WR; Sterker, D; Weiss, A1
Abd Elmageed, ZY; Abdel-Mageed, AB; Kandil, E; Li, X; Ma, J; Mondal, D; Slakey, D; Tsumagari, K1
Bian, XC; Feng, HL; Li, ZW; Liu, YQ; Liu, YY; Yang, ZL1
Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ1
Bartholomeusz, C; Hortobagyi, GN; Kai, K; Kondo, K; Masuda, H; Pitner, MK; Reyes, ME; Saya, H; Sen, S; Torres-Adorno, AM; Tripathy, D; Ueno, NT; Wang, X; Xie, X1
Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A1
Ahn, JS; Ahn, MJ; Bae, YH; Ku, BM; Lee, KY; Lee, SH; Park, K; Sun, JM1
Bedoni, N; Bucher, M; El Zaoui, I; Kaya, G; Leyvraz, S; Moulin, AP; Nicolas, M; Pescini Gobert, R; Riggi, N; Rimoldi, D; Rivolta, C; Sakina, E; Schalenbourg, A; Zografos, L1
Bernards, R; Caumanns, JJ; de Jong, S; Jalving, M; Kol, A; Meersma, GJ; van der Zee, AGJ; van Wijngaarden, A; Wisman, GBA1

Other Studies

10 other study(ies) available for indazoles and azd 6244

ArticleYear
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
    British journal of cancer, 2012, Apr-10, Volume: 106, Issue:8

    Topics: Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Imidazoles; Indazoles; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinolines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases

2012
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; Indazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Sulfonamides; Xenograft Model Antitumor Assays

2012
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    The Journal of surgical research, 2013, Volume: 184, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2013, Volume: 42, Issue:5

    Topics: Apoptosis; bcl-2-Associated X Protein; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Signal Transduction; Sulfonamides

2013
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib

2015
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Mice; Piperazines; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2015
Survival of pancreatic cancer cells lacking KRAS function.
    Nature communications, 2017, 10-23, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles

2017
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Investigational new drugs, 2020, Volume: 38, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras)

2020
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
    Investigative ophthalmology & visual science, 2019, 06-03, Volume: 60, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Conjunctival Neoplasms; Female; Fluorescent Antibody Technique, Indirect; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinolines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2019
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer letters, 2019, Oct-01, Volume: 461

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Benzoxazoles; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019